Beam Therapeutics (BEAM) | Financial Analysis & Statements
Beam Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
114.1M
Operating Income
-17.4M
-15.29%
Net Income
244.3M
214.09%
EPS (Diluted)
$2.33
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
242.8M
Shareholders Equity
1.2B
Debt to Equity
0.20
Cash Flow Metrics
Operating Cash Flow
157.5M
Free Cash Flow
-87.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Beam Therapeutics Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 139.7M | 63.5M | 377.7M | 60.9M | 51.8M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 409.6M | 367.6M | 437.4M | 311.6M | 387.1M |
| Selling, General & Administrative | 113.8M | 111.5M | 116.8M | 87.8M | 57.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 523.4M | 479.1M | 554.2M | 399.4M | 444.3M |
| Operating Income | -383.7M | -415.6M | -176.5M | -338.5M | -392.5M |
| Operating Margin % | -274.6% | -654.3% | -46.7% | -555.6% | -757.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 260.0M | -10.2M | -1.4M | 63.0M | 21.8M |
| Pre-tax Income | -80.0M | -376.7M | -131.2M | -260.2M | -370.6M |
| Income Tax | 0 | 39.0K | 1.4M | 3.4M | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -80.0M | -376.7M | -132.5M | -289.1M | -370.6M |
| Net Margin % | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% |
| Key Metrics | |||||
| EBITDA | -366.2M | -373.7M | -155.1M | -387.3M | -406.8M |
| EPS (Basic) | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 |
| EPS (Diluted) | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 |
| Basic Shares Outstanding | 98905577 | 82313008 | 77151771 | 70015305 | 64227676 |
| Diluted Shares Outstanding | 98905577 | 82313008 | 77151771 | 70015305 | 64227676 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Beam Therapeutics Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 294.9M | 282.0M | 435.9M | 232.8M | 560.0M |
| Short-term Investments | 950.3M | 568.8M | 754.0M | 845.4M | 405.7M |
| Accounts Receivable | - | - | - | 0 | 300.0M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 23.5M | 27.4M | 21.2M | 14.8M | 7.4M |
| Total Current Assets | 1.3B | 878.1M | 1.2B | 1.1B | 1.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 177.7M | 176.7M | 174.5M | 165.9M | 132.6M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 7.3M | 9.4M | 10.9M | 14.7M | 14.5M |
| Total Non-Current Assets | 212.5M | 225.7M | 248.7M | 248.8M | 201.4M |
| Total Assets | 1.5B | 1.1B | 1.5B | 1.3B | 1.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 10.2M | 3.9M | 1.6M | 9.0M | 7.5M |
| Short-term Debt | 14.4M | 13.5M | 12.8M | 10.4M | 7.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 12.4M | 16.2M | 39.0M | 30.6M | 51.5M |
| Total Current Liabilities | 96.9M | 182.1M | 205.6M | 223.6M | 213.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 139.8M | 148.0M | 159.9M | 168.6M | 134.8M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 6.1M | 1.6M | 3.0M | 13.8M | 37.2M |
| Total Non-Current Liabilities | 145.9M | 188.2M | 272.8M | 384.6M | 434.3M |
| Total Liabilities | 242.8M | 370.3M | 478.4M | 608.2M | 647.7M |
| Equity | |||||
| Common Stock | 1.0M | 836.0K | 816.0K | 712.0K | 684.0K |
| Retained Earnings | -1.6B | -1.6B | -1.2B | -1.1B | -768.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.2B | 733.5M | 981.3M | 733.5M | 826.7M |
| Key Metrics | |||||
| Total Debt | 154.1M | 161.4M | 172.7M | 179.0M | 142.4M |
| Working Capital | 1.2B | 696.1M | 1.0B | 869.3M | 1.1B |
Balance Sheet Composition
Beam Therapeutics Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -80.0M | -376.7M | -132.5M | -289.1M | -370.6M |
| Depreciation & Amortization | 22.3M | 31.6M | 20.0M | 14.1M | 7.5M |
| Stock-Based Compensation | 94.2M | 120.7M | 98.6M | 84.3M | 43.6M |
| Working Capital Changes | -143.2M | -47.2M | -177.6M | 276.3M | 66.6M |
| Operating Cash Flow | -82.0M | -273.3M | -191.7M | 75.2M | -94.2M |
| Investing Activities | |||||
| Capital Expenditures | -14.9M | -8.9M | -33.7M | -49.0M | -46.8M |
| Acquisitions | 255.1M | - | 0 | 0 | 620.0K |
| Investment Purchases | -1.2B | -486.4M | -984.3M | -1.6B | -777.2M |
| Investment Sales | 848.2M | 680.4M | 1.1B | 1.2B | 529.3M |
| Investing Cash Flow | -121.4M | 185.0M | 71.8M | -461.3M | -294.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 0 | 0 |
| Debt Repayment | 0 | -485.0K | -2.3M | -2.3M | -2.1M |
| Financing Cash Flow | 470.5M | -485.0K | 267.3M | 105.8M | 746.5M |
| Free Cash Flow | -360.0M | -356.2M | -182.9M | -26.4M | -113.1M |
| Net Change in Cash | 267.1M | -88.7M | 147.4M | -280.3M | 358.2M |
Cash Flow Trend
Beam Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-37.23
Forward P/E
-6.99
Price to Book
2.46
Price to Sales
22.56
PEG Ratio
0.12
Profitability Ratios
Profit Margin
-57.24%
Operating Margin
-15.29%
Return on Equity
-8.11%
Return on Assets
-18.55%
Financial Health
Current Ratio
13.09
Debt to Equity
12.45
Beta
2.19
Per Share Data
EPS (TTM)
$-0.81
Book Value per Share
$12.48
Revenue per Share
$1.41
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BEAM | 3.1B | -37.23 | 2.46 | -8.11% | -57.24% | 12.45 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






